792 results on '"Micallef, Joëlle"'
Search Results
2. Triptan use in elderly over 65 years and the risk of hospitalization for serious vascular events
3. Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020
4. Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox
5. Antibiotic-induced neurological adverse drug reactions
6. Cannabidiol (CBD): Confronting consumers’ expectations of therapeutic benefits with pharmacological reality
7. What should be done to combat misinformation about health products?
8. Quelles actions pour lutter contre la désinformation sur les produits de santé ?
9. Prévention des surdoses opioïdes et diffusion de naloxone (programme POP) : résultats d’un état des lieux réalisé auprès des structures d’addictologie
10. Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice
11. Réalisation d’études pharmacoépidémiologiques à partir du système national des données de santé (SNDS) : application des recommandations dans la pratique
12. Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective
13. Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
14. Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran)
15. Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
16. Analyse des seringues usagées : un reflet de la consommation de substances psychoactives par les usagers de drogues par voie intraveineuse ?
17. Sex differences in adverse drug reactions: Are women more impacted?
18. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: Insights of the annual cross sectional OPPIDUM survey
19. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
20. Quelle place pour l’automatisation intelligente et l’intelligence artificielle pour préserver et renforcer l’expertise en vigilance devant l’augmentation des déclarations ?
21. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data
22. Augmentation de l’abus de méthylphénidate : repérage et profils sur 13 années
23. Pharmacologie du cannabidiol : points de vigilance, conséquences et risques chez l’homme
24. Utilisation de la kétamine chez les patients ambulatoires : que pouvons-nous apprendre des pratiques actuelles ?
25. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007–2019)
26. Author Correction: BDNF Val66Met gene polymorphism modulates brain activity following rTMS-induced memory impairment
27. BDNF Val66Met gene polymorphism modulates brain activity following rTMS-induced memory impairment
28. Prevention of risks associated with inappropriate use/unnecessary consumption of medicines
29. Prévention des risques liés à un usage inapproprié/consommation inutile des médicaments
30. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network
31. Transmucosal fentanyl-related opioid use disorder in a cancer survivor
32. Usages et bon usage des benzodiazépines anxiolytiques et hypnotiques
33. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
34. Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale
35. Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology
36. Analgesic switching in chronic users of dextropropoxyphene in France.
37. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection
38. Addictovigilance contribution during COVID-19 epidemic and lockdown in France
39. Patients’ organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia
40. Orphan drug clinical development
41. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases
42. How to attract doctors to careers in the fields of pharmaceutical medicine and medical devices?
43. Comment intéresser les médecins aux métiers du médicament et des dispositifs médicaux ?
44. What should be done to combat misinformation about health products?*
45. Antibiotic-induced neurological adverse drug reactions
46. Détection des signaux du réseau français d’addictovigilance : méthodes innovantes d’investigation, illustrations et utilité pour la santé publique
47. Améliorer la balance bénéfices/risques de la méthadone en respectant ses spécificités pharmacologiques
48. A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers
49. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution
50. Intérêt de la mise à disposition de la naloxone auprès des usagers de drogues pour le traitement d’urgence de surdosage d’opioïdes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.